Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Biomark Capital Management Co. LLC (CIK 1667082) reported $8.9M across 2 reported positions in its SEC 13F filing for 2018-09-30. Largest positions: ADMA ($8.9M, 99.96%), MBVXQ ($4,000, 0.04%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ADMA | ADMA BIOLOGICS, INC. | $8.9M | 99.96% | 1.4M | Hold |
| 2 | MBVXQ | MABVAX THERAPEUTICS HOLDINGS, INC. | $4,000 | 0.04% | 8,903 | Hold |
Source: SEC Form 13F filings · as of 2018-09-30